...
首页> 外文期刊>American Journal of Surgical Pathology >Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: Comparison of 2 commonly used scoring approaches
【24h】

Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: Comparison of 2 commonly used scoring approaches

机译:新辅助化疗后食管腺癌肿瘤消退的评估:两种常用评分方法的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Histopathologic determination of tumor regression provides important prognostic information for locally advanced gastroesophageal carcinomas after neoadjuvant treatment. Regression grading systems mostly refer to the amount of therapyinduced fibrosis in relation to residual tumor or the estimated percentage of residual tumor in relation to the former tumor site. Although these methods are generally accepted, currently there is no common standard for reporting tumor regression in gastroesophageal cancers. We compared the application of these 2 major principles for assessment of tumor regression: hematoxylin and eosin-stained slides from 89 resection specimens of esophageal adenocarcinomas following neoadjuvant chemotherapy were independently reviewed by 3 pathologists from different institutions. Tumor regression was determined by the 5-tiered Mandard system (fibrosis/tumor relation) and the 4-tiered Becker system (residual tumor in %). Interobserver agreement for the Becker system showed better weighted κ values compared with the Mandard system (0.78 vs. 0.62). Evaluation of the whole embedded tumor site showed improved results (Becker: 0.83; Mandard: 0.73) as compared with only 1 representative slide (Becker: 0.68; Mandard: 0.71). Modification into simplified 3-tiered systems showed comparable interobserver agreement but better prognostic stratification for both systems (log rank Becker: P=0.015; Mandard P=0.03), with independent prognostic impact for overall survival (modified Becker: P=0.011, hazard ratio=3.07; modified Mandard: P=0.023, hazard ratio=2.72). In conclusion, both systems provide substantial to excellent interobserver agreement for estimation of tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. A simple 3-tiered system with the estimation of residual tumor in % (complete regression/1% to 50% residual tumor/>50% residual tumor) maintains the highest reproducibility and prognostic value.
机译:肿瘤消退的组织病理学测定为新辅助治疗后的局部晚期胃食管癌提供了重要的预后信息。回归分级系统主要是指与残留肿瘤有关的治疗引起的纤维化程度或相对于先前肿瘤部位的残留肿瘤的估计百分比。尽管这些方法已被普遍接受,但目前尚无报告胃食管癌肿瘤消退的通用标准。我们比较了这2条主要原则在评估肿瘤消退中的应用:新辅助化疗后89例食管腺癌切除标本中的苏木精和曙红染色玻片由来自不同机构的3位病理学家独立审查。肿瘤消退由5层Mandard系统(纤维化/肿瘤关系)和4层Becker系统(残余肿瘤的百分比)确定。与Mandard系统相比,Becker系统的观察者间协议显示出更好的加权κ值(0.78对0.62)。与仅1个代表性载玻片(Becker:0.68; Mandard:0.71)相比,对整个包埋肿瘤部位的评估显示出改善的结果(Becker:0.83; Mandard:0.73)。修改为简化的三层系统显示出观察者之间的可比性,但两种系统的预后分层更好(对数贝克尔:P = 0.015;曼达德P = 0.03),对整体生存具有独立的预后影响(修正的贝克尔:P = 0.011,危险比) = 3.07;修改后的Mandard:P = 0.023,危险比= 2.72)。总之,这两种系统为食管腺癌新辅助化疗后的肿瘤消退评估提供了重要的观察者一致性。一个简单的3层系统以%的残留肿瘤估计值(完全回归/ 1%至50%残留肿瘤/> / 50%残留肿瘤)可保持最高的可重复性和预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号